A Matt Levine article. But in practice the board-CEO standoff won't go on forever since the NASDAQ delisting deadline is Nov 4 (unless it raises its shares abo

A Matt Levine article. But in practice the board-CEO standoff won't go on forever since the NASDAQ delisting deadline is Nov 4 (unless it raises its shares above $1, which is not gonna happen, and a 20:1 reverse stock split wouldn't help much, and the PR releases about GSK partnership do not appear to reflect any material activity). So tune in next month, around election time. (was the timing of the extended deadline accidental?)